ArticleDermatology reports2026

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy.

Marco May Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.